Milatuzumab doxorubicin/IMMU-110 is the only ADC using doxorubicin while its payload tested inside a phase We/II clinical trial, but was later discontinued [52]. Different ADCs employing DNA-damaging or anti-microtubule payload against the same antigen Currently, 25 ADCs that use DNA-damaging agents mainly because their payloads are either approved by the FDA (gemtuzumab ozogamicin/Mylotarg was withdrawn … Continue reading Milatuzumab doxorubicin/IMMU-110 is the only ADC using doxorubicin while its payload tested inside a phase We/II clinical trial, but was later discontinued [52]